Join

or

Existing user? Login

Helen Meynell

Consultant Pharmacist at Doncaster Royal Infirmary

Recent stories

  • patient with inhaler for COPD

    Role of dual and triple fixed-dose combination inhalers in the treatment of chronic obstructive pulmonary diseaseSubscription

    5 NOV 2018

    A review of the current evidence, including the safety and efficacy of dual and triple-combination inhalers for the treatment of stable COPD, and their place in therapy.

  • Generic prescribing is not appropriate for inhaled drugsSubscription

    8 JAN 2015Comments (3)

    The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing. One product is DuoRespSpiromax, a cheaper “branded generic” of Symbicort Turbohaler, both containing

  • Our concerns with Relvar ElliptaSubscription

    PJ, 22 February 2014, Vol 292, No 7798

    We would like to alert pharmacists to the potential for inadvertent dosing errors that may occur when patients are prescribed the new Relvar Ellipta (fluticasone furoate/vilanterol) inhaler for asthma or chronic obstructive pulmonary disease. Pharmacists should be alert to the fact that the licensed strengths of Relvar Ellipta (92µg/22µg and 184µg/22µg) are equivalent to medium to high doses of fluticasone propionate (500µg and 1,000µg, respectively). There is no low-dose inhaled corti

  • Primum non nocereSubscription

    PJ, 7 June 2014, Vol 292, No 7813

  • Asthma: pathophysiology, causes and diagnosisSubscription

    21 NOV 2014Comments (5)

  • Asthma: long-term managementSubscription

    21 NOV 2014Comments (8)

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.